Zobrazeno 241 - 250
of 1 168
pro vyhledávání: ''
Autor:
T. Gray, Alison Conlin, Carla I. Falkson, Erika Hamilton, Ian E. Krop, Qamar J. Khan, Marc C. Chamberlain, Virginia F. Borges, Ravi Murthy, Cristiano Ferrario
Publikováno v:
Cancer Research. 78:P5-20
Background: Advances in the treatment for HER2+ breast cancer using sequential HER2 targeted therapies has resulted in improvements in outcome. Nonetheless, treatment of HER2+ metastatic breast cancer (MBC) following 1st and 2nd line HER2 targeted th
Autor:
Johannes Ettl, HS Rugo, Eric Gauthier, A. Mori, Aurelio Castrellon, Karen A. Gelmon, C-S Huang, Oleg Lipatov, Nadia Harbeck, DJ Slamon, Anil A. Joy, Richard S. Finn, Véronique Diéras
Publikováno v:
Cancer Research. 78:P5-21
BACKGROUND: Endocrine therapy (ET) has been the primary first-line (1L) therapy for ER+ ABC. In the PALOMA-2 study (NCT01740427), PAL (P)+LET (L) significantly prolonged progression-free survival (PFS; HR=0.58, P METHODS: Postmenopausal pts w/ ER+/HE
Autor:
L de la Pena, Sherene Loi, David N Brown, J Huober, Ian Bradbury, Françoise Rothé, M Maetens, David Venet, J. Baselga, Debora Fumagalli, M Ignatiadis, E. de Azambuja, Nadia Harbeck, Severine Sarp, Paolo Nuciforo, Roberto Salgado, Lajos Pusztai, M.J. Piccart, Christos Sotiriou
Publikováno v:
Cancer Research. 78:GS1-04
Background In the NeoALTTO trial, the combination of trastuzumab and lapatinib for the neoadjuvant treatment of HER2 positive early breast cancer patients (pts) nearly doubled the rate of pathological complete response (pCR) compared with either anti
Autor:
T. Pascual, Marcos Vinicius Silva Oliveira, Laia Paré, Montse Muñoz, Antonia Perelló, Isabel Ruiz, José-Fernán Martínez, Serafin Morales, JC Quero, D. Martinez, Xavier Gonzalez, Aleix Prat, Inmaculada Calvo, Eva Ciruelos, Joaquín Gavilá, M Marín, Antonio Llombart-Cussac, Raquel Andrés, José Francisco Pérez, Jordi Canes, Juan Antonio Virizuela
Publikováno v:
Cancer Research. 78:P2-09
Background. In HER2-positive early breast cancer, neoadjuvant therapy based on dual HER2 blockade with trastuzumab and pertuzumab in combination with chemotherapy is associated with high rates of pCR. The OPTIHER-HEART trial examined the safety of th
Autor:
Brigitte Rack, Ralf Lorenz, V Müller, Wolfgang Janni, Hans Tesch, Georg Heinrich, Eca Bauer, Visnja Fink, Sara Y. Brucker, Inga Bekes, J-U Blohmer, Sven Mahner, Helmut Forstbauer, Twp Friedl, Werner Lichtenegger, Julia Jückstock, Robert E. Coleman, Tanja Fehm, Andreas Schneeweiss, M. W. Beckmann
Publikováno v:
Cancer Research. 78:GS1-06
Background: A recent meta-analysis has reported benefits of adjuvant bisphosphonate treatment in early breast cancer patients with improved breast cancer survival and reduced rate of breast cancer recurrences in the bone, especially in postmenopausal
Autor:
Anthony M. Magliocco, AM DeMichele, Rashmi Krishna Murthy, Kirsten K. Edmiston, J Ritter, LJ Esserman, J Wisell, Y-Y Chen, Jane Perlmutter, Gillian L. Hirst, Erin D. Ellis, Andres Forero-Torres, G Keeney, Kathleen Kemmer, A Tipps, Jay Zeck, AS Clark, F Fan, Husain Sattar, Khalid Amin, G Krings, Ossama Tawfik, Megan L. Troxell, Susan Minton, Sunati Sahoo, Hongzheng Zhang, Stamatakos, A Adams, S Asare, AD Elias, Fraser Symmans, Mara H. Rendi, B Kallakury, Barbara Haley, Molly Klein, T Ocal, A Zelnak, L.J. van 't Veer, Michael Feldman, Sharon Sams, B Datnow, Tuyethoa Vinh, Kathy S. Albain, M Melisko, Je Lang, AJ Chien, K Gwin, Y Fang, Shuko Harada, NM Hylton, X Duan, F Hasteh, Jeffery Mueller, S Thornton, R Tickman, Shi Wei, Qamar J. Khan, N Klipfel, Larissa A. Korde, Judy C. Boughey, Awais Mansoor, Gabrielle M. Baker, Ruby Singhrao, C Ersahin, R Gamez, Donald A. Berry, D Yee, Rita Nanda, Claudine Isaacs, Donald W. Northfelt, Hyo S. Han, Rebecca K. Viscusi, Anne M. Wallace, Christina Yau, L Grasso LeBeau, R Balassanian, Beiyun Chen, N Weidner, HS Rugo
Publikováno v:
Cancer Research. 78:GS3-08
Background: Pathological complete response (pCR) is accepted by FDA as a surrogate endpoint for accelerated approval of targeted agents in combination with chemotherapy based on better long-term outcomes compared to residual disease (Cortazar 2014).
Autor:
John Pollard, Penney, Sara M. Tolaney, H.-T. Arkenau, Geoffrey I. Shapiro, C. Murias, Simon Lord, Emma Dean, G. Conboy, Rui Tang, Carlos Becerra, Melinda L. Telli, Vandana G. Abramson, S.Z. Fields
Publikováno v:
Cancer Research. 78:OT2-07
Background: ATR is a critical regulator of the cellular response to replication stress; it signals DNA damage repair, mediated through homologous recombination. Many cancers depend on ATR to survive DNA damage. M6620 is a potent, selective inhibitor
Autor:
B Xu, F Ma, Q Ouyang, W Li, Z Jiang, Z Tong, Y Liu, H Li, S Yu, J Feng, S Wang, X Hu, X Zhu, J Zou
Publikováno v:
Cancer Research. 78:PD3-08
Background:Pyrotinib is an oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor (TKI) with activity against epidermal growth factor receptor (EGFR) / HER1, HER2, and HER4. Lapatinib in combination with capecitabine is one of the standards o
Autor:
IA Mayer, Yingbo Wang, Dalila Sellami, Dejan Juric, Valentina Boni, M. Campone, Erika Hamilton, S Turri, Anthony Gonçalves, Florian D. Vogl
Publikováno v:
Cancer Research. 78:P5-21
Background Endocrine therapy is the standard first-line treatment for postmenopausal patients (pts) with ER+, HER2– aBC. However, resistance eventually develops, often through dysregulation of PI3K/AKT/mTOR pathway, specifically mutations in PIK3CA
Autor:
Junji Tsurutani, Kaku Saito, Masaya Hattori, Cynthia X. Ma, Haeseong Park, Kenji Tamura, Charles H. Redfern, Hiroji Iwata, Toshihiko Doi, Tsutomu Iwasa, Javad Shahidi, Kan Yonemori, Shinichiro Taira, Caleb Lee, S. Takahashi, Yoichi Naito, Shanu Modi, Bob T. Li, JM Fisher, Takahiro Jikoh, Antoine Yver, Y Kawasaki
Publikováno v:
Cancer Research. 78:PD3-07
Background DS-8201a is a HER2 targeting antibody-drug conjugate (ADC) with high drug to antibody ratio (8:1), a novel linker and topoisomerase I inhibitor as the payload. In preclinical studies, DS-8201a showed efficacy against both trastuzumab emtan